reports
DGAP-News: Vivoryon Therapeutics N.V. new ISIN code
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Corporate Action Vivoryon Therapeutics N.V. new ISIN code 06.01.2021 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics N.V. new ISIN code HALLE (SAALE) / MUNICH, Germany, 06 January 2021 - in connection with the conversion into an N.V., a public company under the laws of the Netherlands (naamloze vennootschap, "N.V.") which has taken effect on 28 November 2020, Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) announces that the shares will be trading under a ne...
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. new...
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. new Home Member State 16.12.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics N.V. new Home Member State HALLE (SAALE) / MUNICH, Germany, 16 December 2020 - as a consequence of the conversion into an N.V., a public company under the laws of the Netherlands (naamloze vennootschap, "N.V.") which has taken effect on 28 November 2020, Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; ISIN DE00...
DGAP-News: Vivoryon Therapeutics N.V.: Successful Relocation of Vivory...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous Vivoryon Therapeutics N.V.: Successful Relocation of Vivoryon Shares Package 14.12.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Successful Relocation of Vivoryon Shares Package HALLE (SAALE) / MUNICH, GERMANY, 14 December 2020 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; ISIN DE0007921835) has been informed by Hauck & Aufhäuser Privatbankiers AG that the remaining stake held by MorphoSys AG, comprising of around 6.5% of the share capital, has been successf...
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics AG Announ...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Corporate Action Vivoryon Therapeutics N.V.: Vivoryon Therapeutics AG Announces Conversion into Vivoryon Therapeutics N.V. 30.11.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics AG Announces Conversion into Vivoryon Therapeutics N.V. HALLE (SAALE) / MUNICH, Germany, 30 November 2020 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY) announced today that it has completed its conversion into an N.V., a public company under the laws of the Netherlands (naamloz...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics Reports Thi...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): 9 Month figures Vivoryon Therapeutics AG: Vivoryon Therapeutics Reports Third Quarter 2020 26.11.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Reports Third Quarter 2020 HALLE (SAALE) / MUNICH, Germany, 26 November 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY; ISIN DE0007921835) announced today its third quarter business update for the period ending September 30, 2020. The third quarter 2020 report is available for download on the Company website ()...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publi...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish its Third Quarter 2020 Business Update on November 26, 2020 19.11.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics AG to Publish its Third Quarter 2020 Business Update on November 26, 2020 HALLE (SAALE) / Munich, Germany, 19 November 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), a biotechnology company focused on developing first-in-class therapeutics target...
DGAP-News: Vivoryon Therapeutics AG: Ordinary General Meeting of Share...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): AGM/EGM Vivoryon Therapeutics AG: Ordinary General Meeting of Shareholders of Vivoryon Therapeutics AG 01.10.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Ordinary General Meeting of Shareholders of Vivoryon Therapeutics AG All proposed resolutions approved with large majority HALLE (SAALE) / MUNICH, Germany, 01 October 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today that its shareholders approved all resolutions proposed by the Comp...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces N...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): AGM/EGM Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces Notice of its Ordinary General Meeting of Shareholders to be Held on September 30, 2020 03.09.2020 / 15:09 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Announces Notice of its Ordinary General Meeting of Shareholders to be Held on September 30, 2020 Â HALLE (SAALE) / MUNICH, GERMANY, 3 September 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) invites all shareholders to Vivoryon...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics AG plans co...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous Vivoryon Therapeutics AG: Vivoryon Therapeutics AG plans conversion into Naamloze Vennootschap (N.V.) under Dutch law 27.08.2020 / 19:10 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics AG plans conversion into Naamloze Vennootschap (N.V.) under Dutch law Vivoryon Therapeutics intends the transfer of the statutory seat to Amsterdam, the Netherlands, leading to a conversion into a public company under the laws of the Netherlands The administrative seat and the bu...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Reports ...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Half Year Results Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Reports Financial Results for H1 2020 and Provides Corporate Update 27.08.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Reports Financial Results for H1 2020 and Provides Corporate Update - Conference call and webcast in English at 3:00 pm CEST / 09:00 am EDT - Vivoryon and Nordic Bioscience collaboration - Meprin protease inhibitors development program  HALLE (SAALE) / MUNICH, Germany,...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publi...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish its Half Year 2020 Results on August 27, 2020 20.08.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics AG to Publish its Half Year 2020 Results on August 27, 2020 HALLE (SAALE) / MUNICH, Germany, 20 August 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), will publish its Half Year Results for 2020 on Thursday, August 27, 2020. The company will host a conference ...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Receives IND Approval fo...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous Vivoryon Therapeutics AG: Vivoryon Receives IND Approval for Varoglutamstat's (PQ912) Phase 2 Study in Alzheimer's Disease 04.08.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Receives IND Approval for Varoglutamstat's (PQ912) Phase 2 Study in Alzheimer's Disease HALLE (SAALE) / Munich, Germany, 04 August 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced that the U.S. Food and Drug Administration (FDA) has cleared the ...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces E...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Study Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces Enrollment of First Patient in VIVIAD, European Phase 2b Alzheimer's Disease Study with Varoglutamstat (PQ912) 15.07.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Announces Enrollment of First Patient in VIVIAD, European Phase 2b Alzheimer's Disease Study with Varoglutamstat (PQ912) Â HALLE (SAALE) / Munich, Germany, 15 July 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics Provides Up...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous Vivoryon Therapeutics AG: Vivoryon Therapeutics Provides Update on US and EU Alzheimer's Clinical Trial Program with PQ912 26.06.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Provides Update on US and EU Alzheimer's Clinical Trial Program with PQ912 Vivoryon and the Alzheimer's Disease Cooperative Study (ADCS) have developed a new trial design for Phase 2a Alzheimer's trial in the US; as a stage gate to Phase 2b EU Alzheimer's trial VIVIAD is exp...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Reports ...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Quarter Results Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Reports First Quarter 2020 14.05.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics AG Reports First Quarter 2020 HALLE (SAALE) / MUNICH, Germany, 14 May 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) announced today its first quarter business update for the period ending March 31, 2020. The first quarter 2020 report is available for download on the Company website: . K...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Postpone...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): AGM/EGM Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Postpones Annual General Meeting 12.05.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics AG Postpones Annual General Meeting  HALLE (SAALE) / Munich, Germany, 12 May 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835) today announced the postponement of the Annual General Meeting which was previously scheduled for June 24, 2020 in Halle (Saale). The decision was made by the Compa...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publi...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous Vivoryon Therapeutics AG: Vivoryon Therapeutics AG to Publish its First Quarter 2020 Business Update on May 14, 2020 07.05.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics AG to Publish its First Quarter 2020 Business Update on May 14, 2020 HALLE (SAALE) / Munich, Germany, 7 May 2020 - Vivoryon Therapeutics AG (Euronext Amsterdam: VVY, ISIN DE0007921835), which develops first-in-class drugs targeting post-translational modifying enzymes, will publish...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces O...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Miscellaneous Vivoryon Therapeutics AG: Vivoryon Therapeutics Announces Outcome of Exclusive Option Deal with MorphoSys 29.04.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Announces Outcome of Exclusive Option Deal with MorphoSys MorphoSys will not execute the option deal to license Vivoryon's small molecule QPCTL inhibitors for oncology  Vivoryon will continue to evaluate QPCTL inhibitors in oncology based on preclinical studies conducted in collaboration w...
DGAP-News: Vivoryon Therapeutics AG: Vivoryon Therapeutics Starts Deve...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Patent Vivoryon Therapeutics AG: Vivoryon Therapeutics Starts Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer's Disease 16.04.2020 / 07:00 The issuer is solely responsible for the content of this announcement. Vivoryon Therapeutics Starts Development Program for Meprin Protease Inhibitors with Intended Therapeutic Use in Fibrosis, Cancer and Alzheimer's Disease HALLE (SAALE) / MUNICH and LEIPZIG, Germany, 16 April 2020 - Vivoryon Therapeutics AG (Euronex...
DGAP-News: Correction of a release from 26/03/2020, 07:00 CET/CEST - V...
DGAP-News: Vivoryon Therapeutics AG / Key word(s): Annual Results Correction of a release from 26/03/2020, 07:00 CET/CEST - Vivoryon Therapeutics AG: Vivoryon Therapeutics AG Reports Full Year 2019 Financial Results 26.03.2020 / 13:10 The issuer is solely responsible for the content of this announcement. CORRECTION: Vivoryon Therapeutics AG Reports Full Year 2019 Financial Results This is a correction of the announcement from 07:00 am CET March 26, 2020. Reason for the correction: > As of December 31, 2019, the Loss per share (basic and diluted) in EUR has been -0.62, c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.